Gilead’s Hepatitis C Treatment Sofosbuvir Rejected in India
News
Gilead Sciences, Inc.‘s application to commercialize novel hepatitis C treatment sofosbuvir in India has been rejected by the country’s patent office, as reported by Reuters. The refusal may open a new ... Read more